Interleukin-17 Inhibitors. A New Era in Treatment of Psoriasis and Other Skin Diseases

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2016 Sep 9

PMID 27605893

Citations 43

Authors

Agnieszka Wasilewska

Marta Winiarska

Malgorzata Olszewska

Lidia Rudnicka

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment - a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).

Citing Articles

Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells.

Kulig P, Luczkowska K, Machalinski B, Baumert B Sci Rep. 2024; 14(1):23559.

PMID: 39384864 PMC: 11464892. DOI: 10.1038/s41598-024-74558-3.

ERK/MEK Pathway Regulates Th17 Cell Differentiation in Patients with Pemphigus Vulgaris.

Han K, Li S, Pan W, Xu M, Zhong M, Zhang W Indian J Dermatol. 2024; 68(6):724.

PMID: 38371571 PMC: 10868988. DOI: 10.4103/ijd.ijd_924_22.

FAM3C/ILEI protein is elevated in psoriatic lesions and triggers psoriasiform hyperproliferation in mice.

Malik B, Vokic I, Mohr T, Poppelaars M, Holcmann M, Novoszel P EMBO Mol Med. 2023; 15(7):e16758.

PMID: 37226685 PMC: 10331587. DOI: 10.15252/emmm.202216758.

Neutrophils as emerging protagonists and targets in chronic inflammatory diseases.

Rawat K, Shrivastava A Inflamm Res. 2022; 71(12):1477-1488.

PMID: 36289077 PMC: 9607713. DOI: 10.1007/s00011-022-01627-6.

The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Akbarzadeh A, Alirezaei P, Doosti-Irani A, Mehrpooya M, Nouri F Dermatol Res Pract. 2022; 2022:4549134.

PMID: 36249714 PMC: 9568340. DOI: 10.1155/2022/4549134.

References

Shabgah A, Fattahi E, Shahneh F . Interleukin-17 in human inflammatory diseases. Postepy Dermatol Alergol. 2014; 31(4):256-61. PMC: 4171672. DOI: 10.5114/pdia.2014.40954. View

Batista D, Perez L, Orfali R, Zaniboni M, Samorano L, Pereira N . Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014; 29(6):1091-5. DOI: 10.1111/jdv.12753. View

Tanemura A, Oiso N, Nakano M, Itoi S, Kawada A, Katayama I . Alopecia areata: infiltration of Th17 cells in the dermis, particularly around hair follicles. Dermatology. 2013; 226(4):333-6. DOI: 10.1159/000350933. View

Zebrowska A, Wagrowska-Danilewicz M, Danilewicz M, Stasikowska-Kanicka O, Cynkier A, Sysa-Jedrzejowska A . IL-17 expression in dermatitis herpetiformis and bullous pemphigoid. Mediators Inflamm. 2013; 2013:967987. PMC: 3732598. DOI: 10.1155/2013/967987. View

Yang J, Sundrud M, Skepner J, Yamagata T . Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci. 2014; 35(10):493-500. DOI: 10.1016/j.tips.2014.07.006. View

Krueger J, Fretzin S, Suarez-Farinas M, Haslett P, Phipps K, Cameron G . IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012; 130(1):145-54.e9. PMC: 3470466. DOI: 10.1016/j.jaci.2012.04.024. View

Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K . Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4):326-38. DOI: 10.1056/NEJMoa1314258. View

Coimbra S, Figueiredo A, Santos-Silva A . Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis. Core Evid. 2014; 9:89-97. PMC: 4112723. DOI: 10.2147/CE.S33940. View

Martin D, Towne J, Kricorian G, Klekotka P, Gudjonsson J, Krueger J . The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2012; 133(1):17-26. PMC: 3568997. DOI: 10.1038/jid.2012.194. View

10.

Chiricozzi A, Krueger J . IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013; 22(8):993-1005. DOI: 10.1517/13543784.2013.806483. View

11.

Nwe S, Champlain A, Gordon K . Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol. 2013; 9(7):677-82. DOI: 10.1586/1744666X.2013.811034. View

12.

Lu R, Zeng X, Han Q, Lin M, Long L, Dan H . Overexpression and selectively regulatory roles of IL-23/IL-17 axis in the lesions of oral lichen planus. Mediators Inflamm. 2014; 2014:701094. PMC: 4121042. DOI: 10.1155/2014/701094. View

13.

Luo Z, Wang H, Wu Y, Sun Z, Wu Y . Clinical significance of IL-23 regulating IL-17A and/or IL-17F positive Th17 cells in chronic periodontitis. Mediators Inflamm. 2014; 2014:627959. PMC: 4265697. DOI: 10.1155/2014/627959. View

14.

Lynde C, Poulin Y, Vender R, Bourcier M, Khalil S . Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014; 71(1):141-50. DOI: 10.1016/j.jaad.2013.12.036. View

15.

Papp K, Leonardi C, Menter A, Ortonne J, Krueger J, Kricorian G . Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366(13):1181-9. DOI: 10.1056/NEJMoa1109017. View

16.

Blauvelt A, Prinz J, Gottlieb A, Kingo K, Sofen H, Ruer-Mulard M . Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2014; 172(2):484-93. DOI: 10.1111/bjd.13348. View

17.

Gelfand J, Weinstein R, Porter S, Neimann A, Berlin J, Margolis D . Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005; 141(12):1537-41. DOI: 10.1001/archderm.141.12.1537. View

18.

Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E . Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012; 366(13):1190-9. DOI: 10.1056/NEJMoa1109997. View

19.

Lonnberg A, Zachariae C, Skov L . Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014; 7:251-9. PMC: 4168861. DOI: 10.2147/CCID.S67534. View

20.

Zhu B, Edson-Heredia E, Cameron G, Shen W, Erickson J, Shrom D . Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013; 169(6):1337-41. DOI: 10.1111/bjd.12610. View